Combining a matrix metalloproteinase inhibitor, a farnesyltransferase inhibitor, and a taxane improves survival in an anaplastic thyroid cancer model

Miaorong She; Sai Ching Jim Yeung

doi:10.1016/j.canlet.2005.07.012

Combining a matrix metalloproteinase inhibitor, a farnesyltransferase inhibitor, and a taxane improves survival in an anaplastic thyroid cancer model

Miaorong She, Sai Ching Jim Yeung

Research output: Contribution to journal › Article › peer-review

14 Scopus citations

Abstract

We previously showed that the in vivo anticancer effects of a combination of manumycin (a farnesyltransferase inhibitor) and paclitaxel (a microtubule inhibitor) against anaplastic thyroid carcinoma (ATC) were partially due to inhibition of angiogenesis. In this study, we investigated the effect of adding minocycline (a matrix metalloproteinase inhibitor) to manumycin and paclitaxel against human ATC cells xenografted in nude mice. The triple-drug combination resulted in the lowest average tumor growth rate, and it conferred significantly better survival than manumycin alone, paclitaxel alone, or manumycin plus paclitaxel. In conclusion, this novel combination deserves further investigation in the treatment of ATC.

Original language	English (US)
Pages (from-to)	197-201
Number of pages	5
Journal	Cancer Letters
Volume	238
Issue number	2
DOIs	https://doi.org/10.1016/j.canlet.2005.07.012
State	Published - Jul 18 2006

Keywords

Angiogenesis inhibition
Human anaplastic thyroid carcinoma
Manumycin
Minocycline
Nude mouse xenograft model
Paclitaxel

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1016/j.canlet.2005.07.012

Cite this

@article{81bcc648fd79455cab31b6d067e1b616,

title = "Combining a matrix metalloproteinase inhibitor, a farnesyltransferase inhibitor, and a taxane improves survival in an anaplastic thyroid cancer model",

abstract = "We previously showed that the in vivo anticancer effects of a combination of manumycin (a farnesyltransferase inhibitor) and paclitaxel (a microtubule inhibitor) against anaplastic thyroid carcinoma (ATC) were partially due to inhibition of angiogenesis. In this study, we investigated the effect of adding minocycline (a matrix metalloproteinase inhibitor) to manumycin and paclitaxel against human ATC cells xenografted in nude mice. The triple-drug combination resulted in the lowest average tumor growth rate, and it conferred significantly better survival than manumycin alone, paclitaxel alone, or manumycin plus paclitaxel. In conclusion, this novel combination deserves further investigation in the treatment of ATC.",

keywords = "Angiogenesis inhibition, Human anaplastic thyroid carcinoma, Manumycin, Minocycline, Nude mouse xenograft model, Paclitaxel",

author = "Miaorong She and {Jim Yeung}, {Sai Ching}",

note = "Funding Information: This research was supported by a grant to SJY from Abbott Laboratories (Thyroid Research Advisory Council). The animal facility at The University of Texas M. D. Anderson Cancer Center is partially supported by the Cancer Center Support Grant (CA16672).",

year = "2006",

month = jul,

day = "18",

doi = "10.1016/j.canlet.2005.07.012",

language = "English (US)",

volume = "238",

pages = "197--201",

journal = "Cancer Letters",

issn = "0304-3835",

publisher = "Elsevier Ireland Ltd",

number = "2",

}

TY - JOUR

T1 - Combining a matrix metalloproteinase inhibitor, a farnesyltransferase inhibitor, and a taxane improves survival in an anaplastic thyroid cancer model

AU - She, Miaorong

AU - Jim Yeung, Sai Ching

N1 - Funding Information: This research was supported by a grant to SJY from Abbott Laboratories (Thyroid Research Advisory Council). The animal facility at The University of Texas M. D. Anderson Cancer Center is partially supported by the Cancer Center Support Grant (CA16672).

PY - 2006/7/18

Y1 - 2006/7/18

N2 - We previously showed that the in vivo anticancer effects of a combination of manumycin (a farnesyltransferase inhibitor) and paclitaxel (a microtubule inhibitor) against anaplastic thyroid carcinoma (ATC) were partially due to inhibition of angiogenesis. In this study, we investigated the effect of adding minocycline (a matrix metalloproteinase inhibitor) to manumycin and paclitaxel against human ATC cells xenografted in nude mice. The triple-drug combination resulted in the lowest average tumor growth rate, and it conferred significantly better survival than manumycin alone, paclitaxel alone, or manumycin plus paclitaxel. In conclusion, this novel combination deserves further investigation in the treatment of ATC.

AB - We previously showed that the in vivo anticancer effects of a combination of manumycin (a farnesyltransferase inhibitor) and paclitaxel (a microtubule inhibitor) against anaplastic thyroid carcinoma (ATC) were partially due to inhibition of angiogenesis. In this study, we investigated the effect of adding minocycline (a matrix metalloproteinase inhibitor) to manumycin and paclitaxel against human ATC cells xenografted in nude mice. The triple-drug combination resulted in the lowest average tumor growth rate, and it conferred significantly better survival than manumycin alone, paclitaxel alone, or manumycin plus paclitaxel. In conclusion, this novel combination deserves further investigation in the treatment of ATC.

KW - Angiogenesis inhibition

KW - Human anaplastic thyroid carcinoma

KW - Manumycin

KW - Minocycline

KW - Nude mouse xenograft model

KW - Paclitaxel

UR - http://www.scopus.com/inward/record.url?scp=33744973546&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33744973546&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2005.07.012

DO - 10.1016/j.canlet.2005.07.012

M3 - Article

C2 - 16154259

AN - SCOPUS:33744973546

SN - 0304-3835

VL - 238

SP - 197

EP - 201

JO - Cancer Letters

JF - Cancer Letters

IS - 2

ER -

Combining a matrix metalloproteinase inhibitor, a farnesyltransferase inhibitor, and a taxane improves survival in an anaplastic thyroid cancer model

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this